"Data complex", but overall positive responses from the panel on #Biogen Aducanumab results. Dr. Stephen Salloway - "Could represent the first therapeutic for Alzheimer's." #CTAD2019 #ENDALZ

67% of trial APOE4+, 42% APOE4+ individuals in high dose group experienced ARIA-E = 27%. Is it possible to identify those who will experience ARIA-E among APOE4+ individuals? Identifying heterogeneity could be helpful in reducing adverse events. Biogen #CTAD2019

Dr. Eliezar Masliah from the ⁦#NIA on future of #Alzheimer’s disease and related dementia trials -#PrecisionsionMedicine is the goal. #CTAD2019

On future of #Alzheimer's drug development - Dr. Paul Aisen “amyloid not the only proteinopathy, and other pathologies beyond tauopathy increase as the disease progresses, including alpha-synuclein and TDP-43 and we need to address multiple proteinopathies” Alzheimer's Therapeutic Research Institute #CTAD2019

Round table on sex/gender consideration in #Alzheimer's clinical trials at #CTAD2019 - Dr. Rachelle Doody "among the challenges are that in certain parts of the world women are not allowed to provide consent" Women's Brain Foundation

How big is the human genome? We barely fit 1/1000 of the human genome sequence typed out on a hallway wall near my office National Human Genome Research Institute! Take a look at the video and see what I mean...

Very cool to have our CEO, Julie Collens, present at TEDxSanDiego this past weekend on why #Alzheimer's drug development is so hard, the potential for #PrecisionMedicine, and the importance of taking up hard challenges. #TEDx

Great to see budget increases to NIH funding to support research, biomarker development, and drug development for #Alzheimer's. 6x increase in funding since the National Alzheimer's Project Act was signed in 2011. #ENDALZ alz.org/news/2019/cong…

My mom died peacefully this afternoon after a decade-long battle with Alzheimer’s / Dementia. Instead of dwelling on the disease that took her away, I would rather acknowledge the successes in her life (see screenshot) And please support HFC and/or Alzheimer's Association

Pre-symptomatic studies in #Alzheimer's will be more and more common, and screening eligible patients will continue to be a challenge. #Precisionmedicine is a more targeted, promising approach. sandiegouniontribune.com/news/health/st…

Please be safe and take care of each other. Science and humanity will get us through.

We're excited to have been selected again as one of San Diego's "Cool Companies"! SDVG

Our founder & CEO Julie Collens was featured on the @TacosandTechPod with Angie.wlfi! Tune in to hear about what brought her to San Diego, her early career, and her entrepreneurial journey. 🌮 bit.ly/3fPtVGY

Hey fam! I'm Dr. Janina Jeff, a human population "Geneti-SIS" who also hosts a dope ass podcast called In Those Genes! Our show uses Black culture and hip hop as a vessel to teach genetics to the Black community #BlackInGenetics #BlackInGeneticsRollCall inthosegenes.com

When #dementia clinical trials have placebo arms that do not decline, it's hard to see a drug effect. Join us at the #ISCTM2020 poster session tomorrow at 11:50am PT as we present the value of genome wide variants beyond APOE to improve predictive models of cognitive decline.

We're presenting this week at CTAD virtual poster hall. Rate of decline affects trials in both pre-screen trial populations and among enrolled individuals; broad genetics improves prediction in both. Posters LP13 & P65 from Nov 4-7 at 1pm ET. #CTAD2020 #ENDALZ

Today the #FDA advisory committee will meet to vote on #aducanumab, which if approved, will be the first disease-modifying #Alzheimers drug. Howard Fillit, MD spoke with @MMarchioneAP to weigh in on this decision, which holds big implications for the community: fal.cn/3bpbu

The landmark approval of @Biogen’s Aduhelm intensifies the need for early detection and screening in Alzheimer’s disease, and highlights the importance of stratification in clinical trials. Vivid Genomics is addressing both of these issues.

Check out our amazing poster in #AAIC21 We use genetics and machine learning to predict Alzheimer's Disease progression rate! #VividGenomics Vivid Genomics

NEW DATA: Topline data from the confirmatory Phase 3 CLARITY AD trial is now available for our investigational anti-amyloid-beta protofibril antibody. #Alzheimersdisease